160 related articles for article (PubMed ID: 1639101)
1. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
[TBL] [Abstract][Full Text] [Related]
3. [Growth characteristics of a human myeloma cell line transfected with IL-6 cDNA].
Takahashi T; Okuno Y; Ohsugi Y
Rinsho Ketsueki; 1993 Apr; 34(4):423-6. PubMed ID: 8510328
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.
Okuno Y; Takahashi T; Suzuki A; Fukumoto M; Nakamura K; Fukui H; Koishihara Y; Ohsugi Y; Imura H
Exp Hematol; 1992 May; 20(4):395-400. PubMed ID: 1568457
[TBL] [Abstract][Full Text] [Related]
6. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
Lasfar A; Wietzerbin J; Billard C
Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
11. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.
Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I
Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
[TBL] [Abstract][Full Text] [Related]
14. Effect of interleukin-6 on the growth of human lung cancer cell line.
Fu J; Zheng J; Fang W; Wu B
Chin Med J (Engl); 1998 Mar; 111(3):265-8. PubMed ID: 10374431
[TBL] [Abstract][Full Text] [Related]
15. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
16. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
17. Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies.
Hirata Y; Taga T; Hibi M; Nakano N; Hirano T; Kishimoto T
J Immunol; 1989 Nov; 143(9):2900-6. PubMed ID: 2681418
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.
Huang YW; Richardson JA; Vitetta ES
Cancer Res; 1995 Feb; 55(3):610-6. PubMed ID: 7834632
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
Demartis A; Bernassola F; Savino R; Melino G; Ciliberto G
Cancer Res; 1996 Sep; 56(18):4213-8. PubMed ID: 8797594
[TBL] [Abstract][Full Text] [Related]
20. [Mechanisms of multiple myeloma cell growth].
Simizu S; Konda S
Rinsho Ketsueki; 1993 Apr; 34(4):418-22. PubMed ID: 8510327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
